文献速递胸部肿瘤

生物标志物整合的新辅助达沙替尼治疗可切除恶性胸膜间皮瘤试验

Biomarker-Integrated Neoadjuvant Dasatinib Trial in Resectable Malignant Pleural Mesothelioma.
PubMed 文献 · J Thorac Oncol · 2017-12-05

该窗口机会试验对24例可切除恶性胸膜间皮瘤患者给予4周口服达沙替尼后手术±放疗,可选2年维持治疗,主要终点为p-SrcTyr419调节。结果显示中位PFS 7.5个月,中位OS 19.1个月,4周后无显著影像学缓解,但p-SrcTyr419 IHC评分中位值从70降至41.9(p=0.004),且下降与PFS改善相关;PDGFRβ高表达与更短PFS相关。

要点

  • 达沙替尼单药在MPM中无显著疗效信号,不继续研究。
  • p-SrcTyr419下降与中位PFS改善相关(6.9 vs 0.94个月,p=0.03)。
  • PDGFRβ高表达(胞质、间质、核)与更短PFS相关。

核心结论

  • 达沙替尼单药在可切除MPM中无显著疗效信号,不继续研究。
  • p-SrcTyr419可作为达沙替尼的药效动力学标志物。
  • PDGFRα与PDGFRβ在预后和抗血管TKIs耐药中可能作用不同,值得进一步研究。

研究设计与样本

  • 窗口机会试验,纳入24例MPM患者。
  • 口服达沙替尼4周后手术±放疗,可选2年维持达沙替尼。
  • 主要终点为p-SrcTyr419生物标志物调节。

主要发现

  • 全体患者中位PFS 7.5个月,中位OS 19.1个月。
  • 达沙替尼治疗4周后无显著缓解。
  • p-SrcTyr419 IHC评分中位值从治疗前70(IQR 37.5-110)降至治疗后41.9(IQR 4.2-60),p=0.004。
  • p-SrcTyr419下降者中位PFS 6.9个月,未下降者0.94个月(p=0.03)。
  • PDGFRβ高表达(胞质HR=2.54,p=0.05;间质HR=2.79,p=0.03;核HR=6.79,p=0.023)与更短PFS相关。

关键数值与推荐

  • 胞质p-PDGFRα IHC低于中位数可预测达沙替尼后PET/CT SUV下降(p=0.04)。
  • PDGFRB IHC高于中位数(胞质HR=2.8,p=0.03;核HR=6.795,p=0.02)与SUV上升相关。

临床怎么用

  • 达沙替尼单药不推荐用于MPM治疗。
  • p-SrcTyr419动态变化可用于评估达沙替尼药效。
  • PDGFR亚型表达可能帮助预后分层及抗血管TKIs耐药机制研究。

局限性

  • 样本量小(N=24),结论需更大样本验证。
  • 为窗口机会试验,无对照组,疗效信号解释受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Window of opportunity trials in malignant pleural mesothelioma (MPM) are challenging but can yield important translational information about a novel agent. METHODS: We treated patients with MPM (N = 24) with 4 weeks of oral dasatinib followed by surgery with or without radiotherapy and then an optional 2 years of maintenance dasatinib. The primary end point was biomarker modulation of phosphorylated (p) SrcTyr419. RESULTS: For all patients, the median progression-free survival (PFS) was 7.5 months and the median overall survival was 19.1 months. No significant responses were seen after 4 weeks of dasatinib therapy; however, modulation of median p-SrcTyr419 immunohistochemistry (IHC) scores was seen: the median pretreatment score was 70 (interquartile range 37.5-110), and the median posttreatment score was 41.9 (interquartile range 4.2-60) (p = 0.004). A decrease in p-SrcTyr419 levels after dasatinib correlated with improved median PFS (6.9 months versus 0.94 months [p = 0.03]), suggesting that p-SrcTyr419 is a viable pharmacodynamic biomarker for dasatinib in MPM. Platelet-derived growth factor receptor (PDGFR) pathway analysis correlated high PDGFR beta [PDGFRB) level (in the cytoplasm [hazard ratio] (HR) = 2.54, p = 0.05], stroma [HR = 2.79, p = 0.03], and nucleus [HR = 6.79, p = 0.023]) with a shorter PFS. Low (less than the median) cytoplasmic p-PDGFR alpha IHC levels were predictive of a decrease in positron emission tomography/computed tomography standard uptake values levels after dasatinib therapy (p = 0.04), whereas higher-than-median IHC scores of PDGFRB (cytoplasmic [HR = 2.8, p = 0.03] and nuclear [HR = 6.795, p = 0.02]) were correlated with rising standard uptake values levels. CONCLUSIONS: In conclusion, there was no significant efficacy signal, and dasatinib monotherapy will not continue to be studied in MPM. However, our study demonstrated that PDGFR subtypes (platelet-derived growth factor receptor alpha and PDGFRB) may have differential roles in prognosis and resistance to antiangiogenic tyrosine kinase inhibitors and are important potential therapeutic targets that require further investigation.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Tsao AS, Lin H, Carter BW, et al. Biomarker-Integrated Neoadjuvant Dasatinib Trial in Resectable Malignant Pleural Mesothelioma. J Thorac Oncol. 2017. PMID: 29313814. doi:10.1016/j.jtho.2017.10.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。